No Data
sonoscape medical corp. (300633) quarterly report review: Pressure is greater in 2024, with a slight decrease in accounts receivable compared to the interim report.
In the third quarter of 2024, the company's revenue was 0.386 billion yuan (a year-on-year decrease of 9.18%), net income attributable to shareholders was -0.062 billion yuan (a year-on-year decrease of 229.50%), and non-net income attributable to shareholders was -0.069 billion yuan (a year-on-year decrease
Sonoscape Medical Corp. (300633): In 2024, the pressure is relatively high, and accounts receivable decreased compared to the interim report.
In the third quarter of 2024, the company's revenue was 0.386 billion yuan (a 9.18% year-on-year decrease), net income attributable to owners of -0.062 billion yuan (a 229.50% year-on-year decrease), non-net income attributable to owners of -0.069 billion yuan (year-on-year
Earnings Miss: SonoScape Medical Corp. Missed EPS And Analysts Are Revising Their Forecasts
Sonoscape Medical Corp. (300633): Performance under pressure within the year, waiting for the equipment update to be implemented.
Investment highlights: Event. The company released the third quarter report of 2024, achieving revenue of 1.398 billion yuan (yoy -4.74%, the same below), net income attributable to the parent company of 0.109 billion yuan (yoy -66.01%), net of non-recurring profit and loss.
Sonoscape Medical Corp. (300633): Performance under pressure, fully prepared for the trough period.
Executive summary of this report: Slow domestic tendering led to income pressure, increased personnel input during the downturn resulted in losses, expected to improve quarter by quarter with the recovery of tendering, maintaining a shareholding rating. Investment highlights: Maintaining a shareholding rating. 2024 Q3 company
Open Healthcare: Report for the third quarter of 2024
